Media Thread, page-7204

Article from yesterday regarding Pfizer on the hunt for deals. Come on, give us some of your cash!

https://endpts.com/amid-revenue-dip-pfizer-ceo-albert-bourla-is-focused-on-whats-next/

Amid revenue dip, Pfizer CEO Albert Bourla is focused on 'what's next'

Pfizer suffered its first quarterly revenue dip since its BioNTech-partnered Covid vaccine was authorized in 2020, CEO Albert Bourla revealed on Tuesday.

And if that isn’t bad enough, he expects patent expiries to cost the company around $17 billion between 2025 and 2030.Which is why, he emphasized on the Q3 call, “It’s all about what’s next.”Bourla outlined ambitious plans to bring 19 new products or indications to market over the next year and a half.

He spies blockbuster potential in more than two-thirds of those, including 15 in-house projects that could earn $20 billion in 2030 alone, he said. Myfembree’s endometriosis indication is on the list, as well as an mRNA flu vaccine expected to launch in 2024, if all goes according to plan.

Chief business innovation officer Aamir Malik added that the company is actively scoping out deals and continues to be “agnostic to size.”“We believe we not only can overcome these expected declines, but also can potentially generate strong growth through the end of the decade,” Bourla said on the call.